We are live on ! Find out more
CBIO

Crescent Biopharma
CBIO

54 hedge funds and large institutions have $46.6M invested in Crescent Biopharma in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

44% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 9

19% more call options, than puts

Call options by funds: $721K | Put options by funds: $607K

15% more funds holding

Funds holding: 47 → 54 (+7)

0.05% more ownership

Funds ownership: 0.52% → 0.58% (+0.05%)

44% less capital invested

Capital invested by funds: $83.1M → $46.6M (-$36.5M)

Holders
54
Holders Change
+7
Holders Change %
+14.89%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
13
Reduced
9
Closed
13
Calls
$721K
Puts
$607K
Net Calls
+$114K
Net Calls Change
-$924K

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$19.3M
2
OCA
Octagon Capital Advisors
New York
+$6.75M
3
Axa
Axa
France
+$3.62M
4
Goldman Sachs
Goldman Sachs
New York
+$1.88M
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$906K

Top Sellers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
-$9.46M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.22M
3
Millennium Management
Millennium Management
New York
-$975K
4
First Manhattan
First Manhattan
New York
-$952K
5
EP
Eversept Partners
New York
-$305K

CBIO Hedge Fund Activity: Q1 2023 in Review

54 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2023, worth a combined $46.6M — down 44% from $83.1M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new CBIO positions and 13 closed out — a net gain of 7 holders — while 13 added to existing stakes and 9 trimmed.

The largest buyer was Artal Group, opening a new position worth an estimated $19.3M. The largest seller was NEA Management Company, cutting an estimated $9.46M.

  • 54 institutional investors held Crescent Biopharma (CBIO) as of Q1 2023, up from 47 in Q4 2022.
  • Funds reported $46.6M of Crescent Biopharma stock for Q1 2023, down 44% quarter-over-quarter.
  • 20 funds opened new Crescent Biopharma positions in Q1 2023 and 13 closed out, a net change of +7 holders.
  • The largest Crescent Biopharma buyer in Q1 2023 was Artal Group, an estimated $19.3M added.
  • The largest Crescent Biopharma seller in Q1 2023 was NEA Management Company, an estimated $9.46M sold.

Based on aggregated 13F filings for Q1 2023.